Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a study in JNCCN – Journal of the National Comprehensive Cancer Network.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
